Oncophenomics

Hyderabad, India

Cancer Diagnostics Medical Devices Precision Medicine/Diagnostics

Oncophenomics (previously Theranosis Life Sciences) is a personalized medicine startup addressing unmet needs in cancer diagnostics, prognostics and theranostics. We are developing microfluidics based lab-on-a-chip medical devices that can detect rare cells such as circulating tumor cells in a simple blood sample drawn from a cancer patient (also known as liquid biopsy) for monitoring the treatment efficacy, predict clinical outcomes and post treatment follow up (surveillance) for cancer recurrence in the form of secondary metastasis. Our patent pending advanced microfluidics chip is designed in such a way so as to capture specific populations of rare cells and perform downstream characterizations. It can be extended beyond cancer research, for example rare fetal cells in maternal blood circulation, circulating endothelial cells in atherosclerosis etc.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Oncophenomics on @MedStartr Today #CancerDiagnosis #CancerMonitoring #MetastaticCancer #Cancer #Diagnostics #MedicalDevices #PrecisionMedicineDiagnostics #MedMo #MedStartrVentures

https://www.medstartr.ai/s/9yAcVbS_1gI

Get Involved in Oncophenomics

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2016
Website: oncophenomics.com/

Disease Areas

Cancer Diagnosis Cancer Monitoring Metastatic Cancer

Technologies

Liquid BiopsyMicrofluidicsMedical DevicesMolecular Diagnostics

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Oncophenomics?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.